-
1دورية أكاديمية
المؤلفون: Fazekas, Tamás, Széles, Ádám D., Teutsch, Brigitta, Csizmarik, Anita, Vékony, Bálint, Kói, Tamás, Ács, Nándor, Hegyi, Péter, Hadaschik, Boris, Nyirády, Péter, Szarvas, Tibor
المصدر: European Urology Oncology ; ISSN 2588-9311
مصطلحات موضوعية: Urology, Radiology, Nuclear Medicine and imaging, Oncology, Surgery
الإتاحة: https://doi.org/10.1016/j.euo.2023.09.001Test
https://api.elsevier.com/content/article/PII:S2588931123001748?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2588931123001748?httpAccept=text/plainTest -
2دورية أكاديمية
المؤلفون: Kovács, Petra Terézia, Mayer, Tamás, Csizmarik, Anita, Váradi, Melinda, Oláh, Csilla, Széles, Ádám, Tschirdewahn, Stephan, Krafft, Ulrich, Hadaschik, Boris, Nyirády, Péter, Riesz, Péter, Szarvas, Tibor
مصطلحات موضوعية: ddc:610, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Urologie, upper urinary tract cancer -- UTUC -- MMP-7 -- matrix metalloproteinase -- biomarker -- prognosis -- immune checkpoint inhibitor therapy -- chemotherapy -- radical nephroureterectomy
العلاقة: https://doi.org/10.3390/biomedicines10030698Test; https://nbn-resolving.org/urn:nbn:de:hbz:465-20220908-160008-4Test; https://duepublico2.uni-due.de/receive/duepublico_mods_00076771Test; https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00076570/biomedicines_2022-10-00698.pdfTest
الإتاحة: https://doi.org/10.3390/biomedicines10030698Test
https://nbn-resolving.org/urn:nbn:de:hbz:465-20220908-160008-4Test
https://duepublico2.uni-due.de/receive/duepublico_mods_00076771Test
https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00076570/biomedicines_2022-10-00698.pdfTest -
3دورية أكاديمية
المؤلفون: Fazekas, Tamás, Széles, Ádám D., Teutsch, Brigitta, Csizmarik, Anita, Vékony, Bálint, Váradi, Alex, Kói, Tamás, Lang, Zsolt, Ács, Nándor, Kopa, Zsolt, Hegyi, Péter, Hadaschik, Boris, Grünwald, Viktor, Nyirády, Péter, Szarvas, Tibor
المصدر: Prostate Cancer and Prostatic Diseases ; volume 26, issue 4, page 665-672 ; ISSN 1365-7852 1476-5608
مصطلحات موضوعية: Cancer Research, Urology, Oncology
الإتاحة: https://doi.org/10.1038/s41391-022-00626-2Test
https://www.nature.com/articles/s41391-022-00626-2.pdfTest
https://www.nature.com/articles/s41391-022-00626-2Test -
4دورية أكاديمية
المؤلفون: Széles, Ádám, Fazekas, Tamás, Váncsa, Szilard, Váradi, Melinda, Kovács, Petra Terézia, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Csizmarik, Anita, Hegyi, Péter, Váradi, Alex, Nyirády, Péter, Szarvas, Tibor
المساهمون: New National Excellence Program, János Bolyai Research Scholarship of the Hungarian Academy of Sciences, Semmelweis University
المصدر: Cancer Immunology, Immunotherapy ; volume 72, issue 5, page 1061-1073 ; ISSN 0340-7004 1432-0851
مصطلحات موضوعية: Cancer Research, Oncology, Immunology, Immunology and Allergy
-
5دورية
المؤلفون: Fazekas, Tamás, Széles, Ádám D., Teutsch, Brigitta, Csizmarik, Anita, Vékony, Bálint, Váradi, Alex, Kói, Tamás, Lang, Zsolt, Ács, Nándor, Kopa, Zsolt, Hegyi, Péter, Hadaschik, Boris, Grünwald, Viktor, Nyirády, Péter, Szarvas, Tibor
المصدر: Prostate Cancer and Prostatic Diseases; December 2023, Vol. 26 Issue: 4 p665-672, 8p
-
6
المؤلفون: Széles, Ádám, Fazekas, Tamás, Váncsa, Szilard, Váradi, Melinda, Kovács, Petra Terézia, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Csizmarik, Anita, Hegyi, Péter, Váradi, Alex, Nyirády, Péter, Szarvas, Tibor
مصطلحات موضوعية: Medizin
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=unidue___bib::955da599e2a52028e3fcdafd3c7f8a1aTest
https://www.ncbi.nlm.nih.gov/pubmed/36385210Test -
7دورية أكاديمية
المؤلفون: Széles, Ádám, Kovács, Petra Terézia, Csizmarik, Anita, Váradi, Melinda, Riesz, Péter, Fazekas, Tamás, Váncsa, Szilárd, Hegyi, Péter, Oláh, Csilla, Tschirdewahn, Stephan, Darr, Christopher, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Horváth, Orsolya, Nyirády, Péter, Szarvas, Tibor
المصدر: Biomedicines; Oct2022, Vol. 10 Issue 10, pN.PAG-N.PAG, 12p
مصطلحات موضوعية: IMMUNE checkpoint proteins, TRANSITIONAL cell carcinoma, PROGRAMMED death-ligand 1, IMMUNE checkpoint inhibitors, IMMUNOTHERAPY, IPILIMUMAB, TUMOR classification